Increased spending on oral anticancer drugs should ideally be driven by increased use because of rising access to care and expanding drug indications.1,2 Yet, prices have risen faster than inflation and are not necessarily reflective of novelty or efficacy.2,3 This study weighs the proportional associations of rising drug costs and use with increased Medicare Part D spending for a cohort of oral anticancer drugs used from 2013 through 2017.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Seiger K, Mostaghimi A, Silk AW, Schmults CD, Ruiz ES. Association of Rising Cost and Use of Oral Anticancer Drugs With Medicare Part D Spending From 2013 Through 2017. JAMA Oncol. Published online November 07, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4906
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: